During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the highlights for patients with TP53-mutated AML from ASH 2020.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
ASH 2020: Highlights for patients with TP53-mutated AML
ASH 2020: Highlights for patients with TP53-mutated AML
Platzbecker highlights the findings from a study evaluating the combination of azacitidine and magrolimab in patients with AML, including TP53-mutant AML.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox